Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System

医学 利托那韦 内科学 人口 队列研究 队列 病毒载量 人类免疫缺陷病毒(HIV) 免疫学 抗逆转录病毒疗法 环境卫生
作者
Scott Dryden-Peterson,Andy Kim,Arthur Kim,Ellen C Caniglia,Inga T. Lennes,Rajesh Patel,Lindsay Gainer,Lisa Dutton,Elizabeth Donahue,Rajesh T Gandhi,Lindsey R Baden,Ann E. Woolley
出处
期刊:Annals of Internal Medicine [American College of Physicians]
标识
DOI:10.7326/m22-2141
摘要

In the EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients) trial, nirmatrelvir plus ritonavir led to an 89% reduction in hospitalization or death among unvaccinated outpatients with early COVID-19. The clinical impact of nirmatrelvir plus ritonavir among vaccinated populations is uncertain.To assess whether nirmatrelvir plus ritonavir reduces risk for hospitalization or death among outpatients with early COVID-19 in the setting of prevalent SARS-CoV-2 immunity and immune-evasive SARS-CoV-2 lineages.Population-based cohort study analyzed to emulate a clinical trial using inverse probability-weighted models to account for anticipated bias in treatment.A large health care system providing care for 1.5 million patients in Massachusetts and New Hampshire during the Omicron wave (1 January to 17 July 2022).44 551 nonhospitalized adults (90.3% with ≥3 vaccine doses) aged 50 years or older with COVID-19 and no contraindications for nirmatrelvir plus ritonavir.The primary outcome was a composite of hospitalization within 14 days or death within 28 days of a COVID-19 diagnosis.During the study period, 12 541 (28.1%) patients were prescribed nirmatrelvir plus ritonavir, and 32 010 (71.9%) were not. Patients prescribed nirmatrelvir plus ritonavir were more likely to be older, have more comorbidities, and be vaccinated. The composite outcome of hospitalization or death occurred in 69 (0.55%) patients who were prescribed nirmatrelvir plus ritonavir and 310 (0.97%) who were not (adjusted risk ratio, 0.56 [95% CI, 0.42 to 0.75]). Recipients of nirmatrelvir plus ritonavir had lower risk for hospitalization (adjusted risk ratio, 0.60 [CI, 0.44 to 0.81]) and death (adjusted risk ratio, 0.29 [CI, 0.12 to 0.71]).Potential residual confounding due to differential access to COVID-19 vaccines, diagnostic tests, and treatment.The overall risk for hospitalization or death was already low (1%) after an outpatient diagnosis of COVID-19, but nirmatrelvir plus ritonavir reduced this risk further.National Institutes of Health.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
正直凡灵发布了新的文献求助10
刚刚
Einsteinwyuh发布了新的文献求助10
刚刚
资浩阑完成签到,获得积分10
刚刚
1秒前
emily发布了新的文献求助10
1秒前
1秒前
sun完成签到 ,获得积分10
1秒前
midx发布了新的文献求助10
1秒前
Na发布了新的文献求助10
2秒前
zhaoyuan完成签到,获得积分10
2秒前
听话的可乐完成签到,获得积分10
3秒前
勤劳的冰淇淋完成签到 ,获得积分10
3秒前
Jeff_Lin完成签到,获得积分10
3秒前
3秒前
领导范儿的应助被程浩磊采纳,获得10
3秒前
xhgxfh发布了新的文献求助10
4秒前
4秒前
4秒前
周青春偶像完成签到,获得积分10
4秒前
ZHOUZHOU完成签到,获得积分10
4秒前
研友_VZG7GZ的应助被单纯的乐曲采纳,获得10
5秒前
核桃发布了新的文献求助10
5秒前
pan发布了新的文献求助10
5秒前
6秒前
6秒前
6秒前
moooo发布了新的文献求助10
8秒前
bbh56发布了新的文献求助10
8秒前
8秒前
好家伙发布了新的文献求助10
9秒前
忧郁蓝调发布了新的文献求助10
10秒前
molihuakai的应助被求知采纳,获得10
10秒前
11秒前
於笑槐完成签到,获得积分10
12秒前
12秒前
Jeff_Lin发布了新的文献求助10
13秒前
maguodrgon发布了新的文献求助10
13秒前
nannan完成签到,获得积分20
14秒前
icymars完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8156628
求助须知:如何正确求助?哪些是违规求助? 9552750
关于积分的说明 21711279
捐赠科研通 7745718
什么是DOI,文献DOI怎么找? 3426593
关于科研通互助平台的介绍 2551401
邀请新用户注册赠送积分活动 2470435